SS
VIRX

SBI Securities’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

SBI Securities’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-180
Closed -$29 – 4255
2024
Q4 		$29 Buy
+180
New +$35 ﹤0.01% 3759

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

SBI Securities's VIRX Position: Q1 2025 in Review

SBI Securities sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 180 shares — an estimated $29 sold.

SBI Securities first reported a position in VIRX in Q4 2024 and held it in 1 quarter. The position peaked at $29 in Q4 2024. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • SBI Securities reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • SBI Securities sold 180 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $29.
  • SBI Securities first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
  • SBI Securities's Viracta Therapeutics, Inc. Common Stock position peaked at $29 in Q4 2024.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on SBI Securities's 13F filing for Q1 2025, filed 2 May 2025.